369 related articles for article (PubMed ID: 7295075)
21. [Medium-sized molecules and the process of uremic intoxication].
Lutz W
Pol Tyg Lek; 1976 Jul; 31(27):1173-6. PubMed ID: 951302
[No Abstract] [Full Text] [Related]
22. Selection of filters and evaluation in vitro of the selective dual filtration artificial kidney, SEDUFARK.
Svartaas TM; Smeby LC; Jørstad S; Naess TB; Widerøe TE; Holtz M
Artif Organs; 1982 May; 6(2):136-44. PubMed ID: 7125956
[TBL] [Abstract][Full Text] [Related]
23. Middle molecule accumulation in uremia: an "extra uremic factor".
Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
[TBL] [Abstract][Full Text] [Related]
24. Extracorporeal strategies for the removal of middle molecules.
Winchester JF; Audia PF
Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
[TBL] [Abstract][Full Text] [Related]
25. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
Maduell F
Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
[TBL] [Abstract][Full Text] [Related]
26. Chronic hemofiltration. A critical evaluation of a new method for the treatment of blood.
Schaefer K; von Herrath D; Gullberg CA; Asmus G; Hüfler M; Offermann G; Cremer H; Heuck CC; Ritz E
Artif Organs; 1978 Nov; 2(4):386-94. PubMed ID: 743012
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and metabolic consequences of uremic toxicity].
Rutkowski P
Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
[TBL] [Abstract][Full Text] [Related]
28. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
[TBL] [Abstract][Full Text] [Related]
29. [Renal replacement therapy by hemodialysis: an overview].
Jacobs C
Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
[TBL] [Abstract][Full Text] [Related]
30. Problems and solutions for artificial kidney.
Vanholder R
Technol Health Care; 2000; 8(6):373-9. PubMed ID: 11258583
[TBL] [Abstract][Full Text] [Related]
31. Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers.
Ouseph R; Hutchison CA; Ward RA
Nephrol Dial Transplant; 2008 May; 23(5):1704-12. PubMed ID: 18156455
[TBL] [Abstract][Full Text] [Related]
32. Middle molecules in uremic serum, urine and dialysis fluid.
Migone L; Dall'taglio P; Buzio C
Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
[TBL] [Abstract][Full Text] [Related]
33. Methodology for identification of serum middle molecules.
Buzio C; Montagna G; Calderini C; Manari A; Migone L
Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
[TBL] [Abstract][Full Text] [Related]
34. [Uremic toxins].
Vanholder R
Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
[TBL] [Abstract][Full Text] [Related]
35. [Uremic toxins. Chromatographic profiles of substances of low and medium molecular weight].
Nesse AB; Arrizurieta de Muchnik E
Medicina (B Aires); 1984; 44(2):117-26. PubMed ID: 6537452
[No Abstract] [Full Text] [Related]
36. Middle molecule definition in terms of membrane permeability.
Klein E
Artif Organs; 1981; 4 Suppl():46-50. PubMed ID: 7295095
[TBL] [Abstract][Full Text] [Related]
37. The consequences of physiological resistances on metabolite removal from the patient-artifical kidney system.
Popovich RP; Hlavinka DJ; Bomar JB; Moncrief JW; Decherd JF
Trans Am Soc Artif Intern Organs; 1975; 21():108-16. PubMed ID: 1145983
[TBL] [Abstract][Full Text] [Related]
38. Serum middle molecule levels in uremia during long term intermittent hemoperfusions with the acac (coated charcoal) microcapsule artificial kidney.
Chang TM; Migchelsen M; Coffey JF; Stark A
Trans Am Soc Artif Intern Organs; 1974; 20A():364-71. PubMed ID: 4217485
[No Abstract] [Full Text] [Related]
39. Urea kinetic and middle molecule approaches to assessing the adequacy of hemodialysis and CAPD.
Keshaviah P
Kidney Int Suppl; 1993 Feb; 40():S28-38. PubMed ID: 8445836
[TBL] [Abstract][Full Text] [Related]
40. [The evaluation of the efficacy of efferent therapy in patients with acute and chronic kidney failure by the spectrum of blood middle-molecule fractions].
Kon'kova TA; Chudnovskaia MV; Golovanov SA
Urol Nefrol (Mosk); 1994; (4):35-7. PubMed ID: 7985299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
